- Home
- LVTX vs XLO Comparison
LVTX vs XLO Comparison
Compare LVTX & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVTX
- XLO
- Stock Information
- Founded
- LVTX 2016
- XLO 2016
- Country
- LVTX Netherlands
- XLO United States
- Employees
- LVTX N/A
- XLO N/A
- Industry
- LVTX Biotechnology: Pharmaceutical Preparations
- XLO Biotechnology: Pharmaceutical Preparations
- Sector
- LVTX Health Care
- XLO Health Care
- Exchange
- LVTX Nasdaq
- XLO Nasdaq
- Market Cap
- LVTX 41.3M
- XLO 35.7M
- IPO Year
- LVTX 2021
- XLO 2021
- Fundamental
- Price
- LVTX $1.55
- XLO $0.70
- Analyst Decision
- LVTX Hold
- XLO Buy
- Analyst Count
- LVTX 4
- XLO 2
- Target Price
- LVTX $1.58
- XLO $3.00
- AVG Volume (30 Days)
- LVTX 115.1K
- XLO 423.3K
- Earning Date
- LVTX 08-13-2025
- XLO 11-06-2025
- Dividend Yield
- LVTX N/A
- XLO N/A
- EPS Growth
- LVTX N/A
- XLO N/A
- EPS
- LVTX N/A
- XLO N/A
- Revenue
- LVTX $4,990,000.00
- XLO $15,001,000.00
- Revenue This Year
- LVTX N/A
- XLO $982.12
- Revenue Next Year
- LVTX N/A
- XLO N/A
- P/E Ratio
- LVTX N/A
- XLO N/A
- Revenue Growth
- LVTX N/A
- XLO 536.45
- 52 Week Low
- LVTX $0.85
- XLO $0.62
- 52 Week High
- LVTX $2.09
- XLO $1.70
- Technical
- Relative Strength Index (RSI)
- LVTX 55.80
- XLO 49.69
- Support Level
- LVTX $1.53
- XLO $0.67
- Resistance Level
- LVTX $1.59
- XLO $0.76
- Average True Range (ATR)
- LVTX 0.03
- XLO 0.03
- MACD
- LVTX -0.00
- XLO 0.00
- Stochastic Oscillator
- LVTX 56.18
- XLO 45.58
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).